Anticancer drug targets: Growth factors and growth factor signaling

Journal of Clinical Investigation

Volumn 105, Issue 1, 2000, Pages 9-13

  Gibbs, Jackson B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 7 HYDROXYSTAUROSPORINE; AMPHIREGULIN; ANTINEOPLASTIC AGENT; CGP 69846A; CISPLATIN; DOCKING PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; ISIS 2503; ISIS 3521; L 778123; L 779450; LEFLUNOMIDE; LONAFARNIB; MIDOSTAURIN; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; NEUROFIBROMIN; ONCOPROTEIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; RAS PROTEIN; TIPIFARNIB; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; UO 126;

AUTOPHOSPHORYLATION; CANCER; DIMERIZATION; DRUG TARGETING; GENE DISRUPTION; GENE MUTATION; LIGAND BINDING; MALIGNANT TRANSFORMATION; ONCOGENE; ONCOGENE NEU; ONCOGENE RAS; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033986112     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9084     Document Type: Review

References (35)

1. Heimbrook, D., Oliff, A., and Gibbs, J.B. 1997. Essentials of signal transduction. 5th edition. Lippincott-Raven Publishers. Philadelphia, PA, 35-45.
2. Vojrek, A.B., and Der Channing, J. 1998. Increasing complexity of the Ras signaling pathway. J. Biol. Chem. 273:19925-19928.
3. Hung, M.C., and Lau, Y.K. 1999. Basic science of HER-2/neu: a review. Semin. Oncol. 26:51-59.
4. Goldenberg, M.M. 1999. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21:309-318.
5. Sliwkowski, M.X., et al. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60-70.
6. Baselga J., Norton, L., Albanell, J., Kim, Y.M., and Mendelsohn, J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825-2831.
7. Baselga, J., et al. 1999. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol. 26:78-83.
8. Shak, S. 1999. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26:71-77.
9. Ewer, M.S., Gibbs, H.R., Swafford, J., and Benjamin, R.S. 1999. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin. Oncol. 26:96-101.
10. Fan, Z., and Mendelsohn, J. 1998. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol. 10:67-73.
11. Yang, X.D., et al. 1999. Eradication of established tumors by a fully human monoclonal antibody in the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1236-1243.
12. Woodburn, J.R., et al. 1997. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proceedings of the American Association for Cancer Research Annual Meeting. 38:633.
13. Moyer, J.D., et al. 1997. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:4838-4848.
14. Singh, J., et al. 1997. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor sub-family of protein tyrosine kinases. J. Med. Chem. 40:1130-1135.
15. Eckhardt, S.G., et al. 1999. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J. Clin. Oncol. 17:1095-1104.
16. Shawver, L.K., et al. 1996. SU101, a potent inhibitor of PDGF-mediated signaling, inhibits growth of a wide variety of tumor types in vivo. Proceedings of the American Association for Cancer Research Annual Meeting. 37:399.
17. Baserga, R., Hongo, A., Rubini, M., Prisco, M., and Valentinis, B. 1997. The IGF-I receptor in cell growth, transformation, and apoptosis. Biochim. Biophys. Acta. 1332:F105-F126.
18. Petley, T., Graff, K., Jiang, W., Yang, H., and Florini, J. 1999. Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm. Metab. Res. 31:70-76.
19. Lowy, D.R., and Willumsen, B.M. 1993. Function and regulation of Ras. Annu. Rev. Biochem. 62:851-891.
20. Holmlund, J.T., Monia, B.P., Kwoh, T.J., and Dorr, F.A. 1999. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Current Opinion in Molecular Therapeutics. 1:372-385.
21. Oliff, A. 1999. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta. 1423:C19-C30.
22. Williams, T.M. 1999. Inhibitors of protein prenylation. Expert opinion on therapeutic patents. 9:1263-1280.
23. Suzuki, N., Urano, J., and Tamanoi, F. 1998. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA. 95:15356-15361.
24. Ferrante, K., Winograd, B., and Canetta, R. 1999. Promising new developments in cancer chemotherapy. Cancer Chemother. Pharmacol. 43(Suppl.):61-68.
25. Moasser, M.M., et al. 1998. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA. 95: 1369-1374.
26. Muschel, R.J., Soto, D.E., McKenna, W.G., and Bernhard, E.J. 1998. Radiosensitization and apoptosis. Oncogene. 17:3359-3363.
27. Liu, M., et al. 1998. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 58:4947-4956.
28. Sun, J.Z., et al. 1999. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranyl-geranyltransferase 1: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 59:4919-4926.
29. Hall-Jackson, C.A., et al. 1999. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6:559-568.
30. Hall-Jackson, C.A., Goedert, M., Hedge, P., and Cohen, P. 1999. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene. 18:2047-2054.
31. Heimbrook, D.C., et al. 1998. Identification of potent, selective kinase inhibitors of Raf. Proceedings of the American Association for Cancer Research Annual Meeting. March. 39:558.
32. Sebolt-Leopold, J.S., et al. 1999. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5:810-816.
33. Favata, M.F., et al. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:18623-18632.
34. Gescher, A. 1998. Analogs of staurosporine: potential anticancer drugs? Gen. Pharmacol. 31:721-728.
35. Du, W., Liu, A., and Prendergast, G.C. 1999. Activation of the P13′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res. 59:4208-4212.